Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma

Journal of Thoracic Oncology

Volumn 2, Issue 3, 2007, Pages 203-209

  Langer, Corey J ^a   Somer, Robert ^a   Litwin, Samuel ^a   Feigenberg, Steven ^a   Movsas, Benjamin ^a   Maiale, Christine ^a   Sherman, Eric ^a   Millenson, Michael ^a   Nicoloau, Nicos ^a   Huang, Chao ^a   Treat, Joseph ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cisplatin; Irinotecan; Locally advanced NSCLC; Phase I study; Radical thoracic radiation

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CISPLATIN; DIPHENOXYLATE; FUROSEMIDE; GRANISETRON; IRINOTECAN; LOPERAMIDE; MANNITOL; ONDANSETRON; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LUNG ASPERGILLOSIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; WEIGHT REDUCTION; CANCER STAGING; LUNG TUMOR; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING;

EID: 34247151161     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318031cd3c     Document Type: Article

References (47)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung: non-small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA (Eds.), Cancer Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott, 1993. Pp 673-723.
2. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the RTOG. Cancer 1987;59:1874.
3. Bell D, Matthews J, Worotnink V, Oreuna E. Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;25:599-604.
4. Bleehan NM, Cox JD. Radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1985;11:1001-1007.
5. Cox JD, Komaki R, Byhardt RW. Is immediate radiation therapy indicated for patients with unresectable non-small cell lung cancer? Yes. Cancer Treat Rep 1983;67:327-331.
6. Payne DG. Non-small cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy? J Clin Oncol 1998;6:552-558.
7. Berry RJ, Laing AH, Newman CR, Peto J. The role of radiotherapy in treatment of inoperable lung cancer. Int J Radiat Oncol Biol Phys 1977;2:433-439.
8. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable, non-small cell lung cancer. Ann Int Med 1990;113:33-38.
9. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-945.
10. Dillman RO, Seagren SL, Hendon J, et al. Randomized trial of induction chemotherapy plus radiation therapy (RT) vs RT alone in stage III non-small cell lung cancer: five-year follow-up of CALGB 84-33. Proc Am Soc Clin Oncol 1996;12:329.
11. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial of regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
12. Sause WT, Kolesar P, Taylor S, et al. Five-year results: phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8892. Proc Am Soc Clin Oncol 1998;17:A-1743.
13. LeChevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1990;83:417-423.
14. LeChevalier T, Arriagada R, Quoix E, et al. Significant effect of adjuvant chemotherapy or survival in locally advanced non-small cell lung carcinoma (letter). J Natl Cancer Inst 1992;84:58.
15. Schaake-Konig C, Van der Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-530.
16. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995;13:452-458.
17. Jeremic B, Shibamato Y, Acimovic L. Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.
18. Furuse K, Fukuoka M, Takada Y, et al. A randomized phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 1997;16:1649a.
19. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable, stage III NSCLC: initial report of RTOG 9410. Proc Am Soc Clin Oncol 2001;20:A-1891.
20. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC. Proc Am Soc Clin Oncol 2003;23:621.
21. Muggia FM, Creaven PJ, Hansen JJ, et al. Phase I trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-521.
22. Yokokura T, Furuta T, Sawada S, et al. Antitumor activity of newly synthesized, lactone ring-closed and water-soluble camptothecin derivative in mice. Proceedings of the Japanese Cancer Association, 43rd Annual Meeting, Fukuoka, Japan, 1984. P. 261.
23. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5947.
24. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878.
25. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-1726.
26. Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of the combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993;84:203-207.
27. Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991;18:607-612.
28. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992;10:16-20.
29. Negoro S, Fukuoka M, Masuda N, et al. A phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin in the treatment of non-small cell lung cancer. J Natl Cancer Inst 1991;83:1164-1168.
30. Douillard JY, Ibrahim N, Riviere A, et al. A phase II study of CPT=11 in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995;14:365.
31. Kameyama M, Noainoue S, Ohtsuka K, Takaoka K, Iraya Y, Kanetoshi A. Activation and detoxification of CPT-11 by human lung cancer cells. Proc Am Soc Clin Oncol 2000;19:A-1975.
32. Masuda N, Fukuoka M, Fujita A, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small cell lung cancer. Br J Cancer 1998;78:251-256.
33. Ueoka H, Kiura K, Hireki S, et al. Fractionated administration of cisplatin and irinotecan in patients with stage IIIB and IV non-small cell lung cancer: a phase II study. Proc Am Soc Clin Oncol 1999;18:A-2026.
34. Mori K, Machida S, Yoshida T, Noda M, Tominaga K. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte: a stimulating factor support for advanced non-small cell lung cancer. Eur J Cancer 1999;35(suppl 4):261.
35. Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer 2003;39:201-7.
36. Masuda N, Fukuoka M, Nagoro S, et al. A randomized trial comparing cisplatin and irinotecan vs cisplatin and vindesine vs CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc Am Soc Clin Oncol 1999;18:A-1774.
37. Niho S, Nagao K, Nishiwaki Y, et al. A randomized multicenter phase III trial of irinotecan and cisplatin vs cisplatin and vindesine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:A1897.
38. Kunitoh H, Saijo N, Nagao K, Ohashi Y, Niitani H. Cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) in advanced (stager IIIB and stage IV) non-small cell lung cancer (NSCLC). A multicenter phase III study. Eur J Cancer 1999; 35(suppl 4):S249.
39. DeVore RF, Johnson DH, Crawford J, et al. A phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Onc 1999;17:2710-2720.
40. Jagasia M, Langer C, Yunis F, et al. Preliminary results of a multicenter phase II trial of weekly cisplatin and irinotecan in patients with advanced non-small cell lung cancer (NSCLC): a Vanderbilt Cancer Center affiliate network study. Proc Am Soc Clin Oncol 1999;18:510a.
41. Tamura K, Takada M, Kawase I, et al. Enhancement of tumor radio-response by irinotecan in human lung cancer xenografts. Jpn J Cancer Research 1997;88:218-223.
42. Takeda K, Negoro S, Kudoh S, et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999;79:1462-1467.
43. Oka M, Fakuda M, Fakuda M, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur J Cancer 2001;37:1359-1365.
44. Yamada M, Kudoh S, Negoro S, Yamamoto N, Nakagawa K, Fukuoka M. A phase I study of irinotecan and carboplatin with concurrent thoracic radiotherapy for unresectable stage III NSCLC. Proc Am Soc Clin Oncol 1999;18:528a.
45. Kawahara M, Hosoe S, Fukuoka M, et al. A phase II study of induction chemotherapy with CPT-11 and cisplatin followed by thoracic radiotherapy combined with weekly CPT-11 in patients with unresectable stage III NSCLC: final results of Japan Clinical Oncology Group (JCOG) protocol 9706. Proc Am Soc Clin Oncol 2002;21:A-1262.
46. Choy H, Chakravarthy A, DeVore 3rd, RF et al. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology 2000;14(7 suppl 5):43-46.
47. Chakravarthy A, Choy H. A phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non-small cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial. Clin Lung Cancer 2000;1:310-311.